...
首页> 外文期刊>Regulatory peptides. >Adrenomedullin((27-52)) inhibits vascular calcification in rats.
【24h】

Adrenomedullin((27-52)) inhibits vascular calcification in rats.

机译:肾上腺髓质素((27-52))抑制大鼠血管钙化。

获取原文
获取原文并翻译 | 示例

摘要

Adrenomedullin (ADM) has the vasodilatory properties and involves in the pathogenesis of vascular calcification. ADM could be degraded into more than six fragments in the body, including ADM((27-52)), and we suppose the degrading fragments from ADM do the same bioactivities as derived peptides from proadrenomedullin. The present study carries forward by assessing the effects on vascular calcification of the systemic administration of ADM((27-52)). The rat vascular calcific model was replicated with vitamine D(3) and nicotine. ADM or/and ADM((27-52)) were systemically administrated with mini-osmotic pump beginning at seventh day after the model replication for 25 days. Vascular calcific nodules histomorphometry, vascular calcium content, vascular calcium uptake, alkaline phosphatase activity, and osteopontin-mRNA quantification in aorta were assessed. ADM limited 40.2% vascular calcific nodules (P<0.01), did not effect on calcium content (P>0.05), reduced 44.4% calcium uptake (P<0.01), lowered 21.1% alkaline phosphatase activity (P<0.01), and regulated 40.9% downwards osteopontin-mRNA expression (P<0.01) in the aorta of rats with vascular calcification. ADM((27-52)) receded 32.0% vascular calcific nodules (P<0.01), taken from 55.5% calcium content (P<0.01), did not affect calcium uptake (P>0.05), inhibited 22.5% alkaline phosphatase activity (P<0.01), and restrained 21.9% osteopontin-mRNA expression (P<0.01) in the aorta of rats with vascular calcification. Both of ADM and ADM((27-52)) did interact on vascular calcification each other. ADM could partially antagonize the effects of ADM((27-52)) in taking from calcium content (17.5%, P<0.01) and in receding vascular calcific nodules (18.6%, P<0.01). ADM could obviously enhance the action of ADM((27-52)) in inhibiting alkaline phosphatase activity (14.4%, P<0.01) and in reducing calcium uptake (11.4%, P<0.01). ADM((27-52)) could partially antagonize the effects of ADM on regulating downwards osteopontin-mRNA expression (17.0%, P<0.01). It is concluded that ADM((27-52)) derived from ADM acts as an inhibitory agent on vascular calcification, with special mechanisms different from ADM derived from ADM progenitor molecule.
机译:肾上腺髓质素(ADM)具有血管舒张特性,并参与血管钙化的发病机理。 ADM可以在体内降解为六个以上的片段,包括ADM((27-52)),并且我们假设ADM的降解片段具有与原肾上腺髓质素衍生的肽相同的生物活性。本研究通过评估ADM全身给药对血管钙化的影响((27-52))进行。用维生素D(3)和尼古丁复制大鼠血管钙化模型。在模型复制25天后的第七天开始,用微型渗透泵全身性地给予ADM或/和ADM((27-52))。评估了血管钙化结节的组织形态,血管钙含量,血管钙摄取,碱性磷酸酶活性以及主动脉中骨桥蛋白-mRNA的含量。 ADM限制了40.2%的血管钙化结节(P <0.01),对钙含量没有影响(P> 0.05),降低了44.4%的钙摄取(P <0.01),降低了21.1%的碱性磷酸酶活性(P <0.01),并且受到调节血管钙化大鼠主动脉中骨桥蛋白-mRNA表达下降40.9%(P <0.01)。 ADM((27-52))从55.5%的钙含量(P <0.01)中减少了32.0%的血管钙化结节(P <0.01),不影响钙的吸收(P> 0.05),抑制了22.5%的碱性磷酸酶活性( P <0.01),并抑制血管钙化大鼠主动脉中骨桥蛋白-mRNA表达21.9%(P <0.01)。 ADM和ADM((27-52))确实在血管钙化上相互作用。 ADM可以部分拮抗ADM((27-52))的钙含量(17.5%,P <0.01)和减少血管钙化结节(18.6%,P <0.01)的作用。 ADM可以明显增强ADM((27-52))在抑制碱性磷酸酶活性(14.4%,P <0.01)和减少钙摄取(11.4%,P <0.01)方面的作用。 ADM((27-52))可以部分拮抗ADM对下调骨桥蛋白-mRNA表达的作用(17.0%,P <0.01)。结论是,源自ADM的ADM((27-52))作为血管钙化的抑制剂,具有不同于源自ADM祖先分子的ADM的特殊机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号